Evidence map›Paper›PMID 39377576›Full record

ArticlemBio2024

A

Yishak A Woldetsadik, David W Lazinski, Andrew Camilli

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Phage RyR-domain proteins degrade ADPR-based immune signals and fuel NADbioRxiv : the preprint server for biology · 2026
    Article
  2. Lineage-specific defence systems of pandemicPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025
    Review
  3. Article
4 · The record

Corrections and comments

  • Update of
    A2024
5 · Who and what money

Authors and funding

3 authors.

Yishak A WoldetsadikDepartment of Molecular Biology and Microbiology, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0003-4237-6615
David W LazinskiDepartment of Molecular Biology and Microbiology, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.
Andrew CamilliDepartment of Molecular Biology and Microbiology, Graduate School of Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0002-1521-5894

Funding

Study of transmissible forms of Vibrio CholeraeR01AI055058 · NIAID · TUFTS UNIVERSITY BOSTON · PI CAMILLI, ANDREW · 2003 to 2019
$5.8M
Phage Resistance in Emergent Vibrio cholerae and Phage Prophylaxis of CholeraR37AI055058 · NIAID · TUFTS UNIVERSITY BOSTON · PI Andrew Camilli · 2020 to 2026
$3.4M
Molecular Genetics of Basic Cell FunctionT32GM139772 · NIGMS · TUFTS UNIVERSITY BOSTON · PI Andrew Camilli · 2022 to 2026
$1.3M
Mechanisms of Phage Predation on Environmental Vibrio choleraeR21AI147658 · NIAID · TUFTS UNIVERSITY BOSTON · PI CAMILLI, ANDREW · 2019 to 2020
$452k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI055058HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI147658HHS | NIH | National Institute of General Medical Sciences (NIGMS) GM139772NIAID NIH HHS R01 AI055058NIAID NIH HHS R21 AI147658NIAID NIH HHS R37 AI055058NIGMS NIH HHS T32 GM139772
6 · The paper itself

Abstract

Bacteria and their predatory viruses (bacteriophages or phages) are in a perpetual molecular arms race. This has led to the evolution of numerous phage defensive systems in bacteria that are still being discovered, as well as numerous ways of interference or circumvention on the part of phages. Here, we identify a unique molecular battle between the classical biotype of

Indexed as

BacteriophagesNADVibrio choleraeBacterial ProteinsGenomic IslandsVirulenceVirus ReplicationBacterial ProteinsNADbacteriophage evolutionbacteriophage immunitybacteriophagescholeraVibrio cholerae

Identifiers

PMID39377576
PMCPMC11559045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.